Form 8-K - Current report:
SEC Accession No. 0001564590-22-008042
Filing Date
2022-03-01
Accepted
2022-03-01 16:15:41
Documents
14
Period of Report
2022-03-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rna-8k_20220301.htm   iXBRL 8-K 37603
2 EX-99.1 rna-ex991_6.htm EX-99.1 279806
3 GRAPHIC goyegqyj5132000001.jpg GRAPHIC 206622
  Complete submission text file 0001564590-22-008042.txt   709018

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA rna-20220301.xsd EX-101.SCH 5730
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE rna-20220301_lab.xml EX-101.LAB 19433
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rna-20220301_pre.xml EX-101.PRE 11612
8 EXTRACTED XBRL INSTANCE DOCUMENT rna-8k_20220301_htm.xml XML 3565
Mailing Address 10578 SCIENCE CENTER DRIVE SUITE 125 SAN DIEGO CA 92121
Business Address 10578 SCIENCE CENTER DRIVE SUITE 125 SAN DIEGO CA 92121 858-401-7900
Avidity Biosciences, Inc. (Filer) CIK: 0001599901 (see all company filings)

EIN.: 461336960 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39321 | Film No.: 22698195
SIC: 2834 Pharmaceutical Preparations